Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD

REFERENCES

• Celli B R, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute. World Health Organization. 2006
   Google Scholar
• Casaburi R, Briggs D D, Jr., Donohue J F, Serby C W, Menjoge S S, Witek T J, Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118: 1294–1302
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P W, Wanner A, San P G, ZuWallack R L, Menjoge S S, Serby C W, Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–224
   PubMed Web of Science ®Google Scholar
• Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441–1449
   PubMed Web of Science ®Google Scholar
• Dahl R, Greefhorst L A, Nowak D, Nonikov V, Byrne A M, Thomson M H, Till D, Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–784
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine B E, Thomson M H, Till D, Kottakis J, Della Cioppa G. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058–1069
   PubMed Web of Science ®Google Scholar
• Rennard S I, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087–1092
   PubMed Web of Science ®Google Scholar
• Mahler D A, Donohue J F, Barbee R A, Goldman M D, Gross N J, Wisniewski M E, Yancey S W, Zakes B A, Rickard K A, Anderson W H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–965
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Cooper C B. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–259
   PubMed Web of Science ®Google Scholar
• Richter K, Stenglein S, Mucke M, Sieder C, Schmidtmann S, Harnest U, Weidinger G, Magnussen H. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006; 73: 414–419
   PubMed Web of Science ®Google Scholar
• van Noord J A, Aumann J L, Janssens E, Verhaert J, Smeets J J, Mueller A, Cornelissen P J. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509–517
   PubMed Web of Science ®Google Scholar
• Rennard S I, Stoner J A. Challenges and opportunities for combination therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 391–393, discussion 394–395
   PubMedGoogle Scholar
• Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera M G, Centanni S. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17: 35–39
   PubMed Web of Science ®Google Scholar
• van Noord J A, Aumann J L, Janssens E, Smeets J J, Verhaert J, Disse B, Mueller A, Cornelissen P J. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–222
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006; 100: 1925–1932
   PubMed Web of Science ®Google Scholar
• Tashkin D P, Littner M, Andrews C P, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: A placebo-controlled trial. Respir Med 2008; 102: 479–487
   PubMed Web of Science ®Google Scholar
• Mahler D A, Weinberg D H, Wells C K, Feinstein A R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751–758
   PubMed Web of Science ®Google Scholar
• Jones P W, Quirk F H, Baveystock C M. The St George's Respiratory Questionnaire. Respir Med 1991; 85(Suppl B)25–31, discussion 33–37
   PubMed Web of Science ®Google Scholar
• Donohue J F. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111–124
   PubMedGoogle Scholar
• Littner M R, Ilowite J S, Tashkin D P, Friedman M, Serby C W, Menjoge S S, Witek T J, Jr. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136–1142
   PubMed Web of Science ®Google Scholar
• Cazzola M, Centanni S, Regorda C, di Marco F, di Perna F, Carlucci P, Boveri B, Santus P. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther 2001; 14: 41–45
   PubMed Web of Science ®Google Scholar
• Cazzola M, Di Perna F, Califano C, Vinciguerra A, D'Amato M. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Pulm Pharmacol Ther 1999; 12: 267–271
   PubMed Web of Science ®Google Scholar